Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
This Week in Virology - TWiV 972: Clinical update with Dr. Daniel Griffin

TWiV 972: Clinical update with Dr. Daniel Griffin

This Week in Virology

01/07/23 • 42 min

plus icon
bookmark
Share icon

In his weekly clinical update Dr. Griffin discusses the infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave, virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants, antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants, comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans, time to negative PCR conversion among high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated by Sotrovimab or Nirmatrelvir, COVID drug Paxlovid was hailed as a game-changer, what happened?, the Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice, SARS-CoV-2 infection and persistence in the human body and brain at autopsy, long-term cardiovascular outcomes of COVID-19, and how heart-disease risk soars after COVID — even with a mild case.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

01/07/23 • 42 min

2 Listeners

plus icon
bookmark
Share icon

Generate a badge

Get a badge for your website that links back to this episode

Select type & size
Open dropdown icon
share badge image

<a href="https://goodpods.com/podcasts/this-week-in-virology-80331/twiv-972-clinical-update-with-dr-daniel-griffin-27264303"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to twiv 972: clinical update with dr. daniel griffin on goodpods" style="width: 225px" /> </a>

Copy